PedAM
Pediatric Disease Annotations & Medicines
| Disease | subependymal giant cell astrocytoma |
| Phenotype | C0041341|tuberous sclerosis complex |
| Sentences | 28 |
| PubMedID- 25227171 | Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. |
| PubMedID- 23158522 | Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (exist-1): a multicentre, randomised, placebo-controlled phase 3 trial. |
| PubMedID- 23231513 | Everolimus (rad001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 26381530 | Objective: to analyze the cumulative efficacy and safety of everolimus in treating subependymal giant cell astrocytomas (sega) associated with tuberous sclerosis complex (tsc) from an open-label phase ii study (nct00411619). |
| PubMedID- 20133820 | Novel proteins regulated by mtor in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. |
| PubMedID- 26248290 | Another report using everolimus as a treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex for approximately 3 years found the most frequent adverse events were also aphthous stomatitis and respiratory infections in children under 3 years of age, and no significant neuropsychological changes were noticed between baseline and follow-up [22]. |
| PubMedID- 23391693 | Management of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc): clinical recommendations. |
| PubMedID- 24667738 | This analysis focuses on the clinical presentation, management, and associated burden of subependymal giant cell astrocytomas in patients with tuberous sclerosis complex in the united states. |
| PubMedID- 22805244 | Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 23567018 | Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 24507694 | Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. |
| PubMedID- 24105488 | subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention. |
| PubMedID- 24056156 | Congenital segmental lymphedema in tuberous sclerosis complex with associated subependymal giant cell astrocytomas treated with mammalian target of rapamycin inhibitors. |
| PubMedID- 24757527 | Everolimus is effective in the treatment of large angiomiolypomas (aml) in patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc). |
| PubMedID- 23686401 | Everolimus is a mammalian target of rapamycin (mtor) inhibitor approved for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma associated with tuberous sclerosis complex, renal angiomyolipoma and tuberous sclerosis complex, and, in combination with exemestane, for hormone receptor-positive her2-negative advanced breast cancer after failure of treatment with letrozole or anastrozole. |
| PubMedID- 25493579 | [subependymal giant cell astrocytoma associated with tuberous sclerosis complex - pharmacological treatment using mtor inhibitors]. |
| PubMedID- 23138436 | The authors describe a rare case of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex that presented with intratumoral bleeding with extension to the ventricles. |
| PubMedID- 25456370 | Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised exist-1 study. |
| PubMedID- 20887114 | Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. |
| PubMedID- 22136276 | Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 23183057 | The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. |
| PubMedID- 25682485 | Conclusion: everolimus is a promising pharmacological approach to treat clinically significant inoperable cardiac rhabdomyomas or subependymal giant cell astrocytoma associated with tuberous sclerosis complex during the neonatal period. |
| PubMedID- 23489586 | Currently, the food and drug administration (fda) has approved cci-779 for the treatment of advanced renal cell carcinoma, and rad001 for the treatment of advanced renal cell carcinoma, subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc), progressive neuroendocrine tumors of pancreatic origin, and postmenopausal women with advanced hormone-receptor-positive, her2-negative breast cancer (in combination with exemestane). |
| PubMedID- 25557360 | Background: the aim of the study was to investigate factors affecting response to everolimus, a mammalian-target-of-rapamycin (mtor) inhibitor, of subependymal giant cell astrocytomas (sega) in patients with tuberous sclerosis complex (tsc). |
| PubMedID- 25143481 | Everolimus treatment for an early infantile subependymal giant cell astrocytoma with tuberous sclerosis complex. |
| PubMedID- 23325902 | Objective: to report long-term efficacy and safety data for everolimus for the treatment of subependymal giant cell astrocytoma (sega) in patients with tuberous sclerosis complex (tsc). |
| PubMedID- 21297924 | From the bench to the bedside: everolimus for subependymal giant cell astrocytomas in tuberous sclerosis complex, optic nerve regeneration, targeted cytotoxins for gliomas. |
| PubMedID- 20643042 | [subependymal giant cell astrocytoma in tuberous sclerosis complex. |
Page: 1